PolyPid Ltd. (PYPD) 10-Year Financial Performance & Capital Metrics

PYPD • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutPolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Show more

Revenue $0
EBITDA -$26M -25.5%
Net Income -$29M -21.6%
EPS (Diluted) -4.91 +71.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1038.73% +18.8%
ROIC -733.23% -222.4%
Debt/Equity 1.25
Interest Coverage -18.38 -37.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM75.57%

ROCE

10Y Avg-211.77%

5Y Avg-145.16%

3Y Avg-198.76%

Latest-271.8%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-108K	-127K	-205K	-411K	-947K	-1.01M	-1.12M	-1.72M	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.18%	-0.61%	-1%	-1.3%	-0.07%	-0.1%	-0.54%	1%	-
Operating Expenses+	8.57M	10.26M	13.8M	18.36M	17.61M	25.26M	42.03M	37.17M	22.87M	28.03M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.93M	2.55M	4.06M	5.81M	3.53M	9.32M	12.45M	10.9M	6.72M	5.22M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.63M	7.71M	9.74M	12.55M	14.08M	16.95M	30.42M	27.99M	16.15M	22.81M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	-1.01M	-848K	-1.72M	0	0
Operating Income+	-11.28M	-10.26M	-13.8M	-18.36M	-18.56M	-26.27M	-43.15M	-38.89M	-22.87M	-28.03M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.15%	0.09%	-0.35%	-0.33%	-0.01%	-0.42%	-0.64%	0.1%	0.41%	-0.23%
EBITDA+	-11.17M	-10.13M	-13.6M	-17.95M	-17.61M	-25.26M	-42.03M	-37.17M	-21.05M	-26.41M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.18%	0.09%	-0.34%	-0.32%	0.02%	-0.43%	-0.66%	0.12%	0.43%	-0.25%
D&A (Non-Cash Add-back)	108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	1.82M	1.62M
EBIT	-8.06M	-11.28M	-54.47M	5.96M	-6.89M	-36.87M	-42.6M	-38.09M	-22.87M	-28.03M
Net Interest Income+	-1.69M	-37K	74K	84K	45K	457K	468K	-1.07M	-1.16M	-1.08M
Interest Income	0	71K	90K	126K	60K	474K	468K	267K	548K	442K
Interest Expense	1.69M	108K	16K	42K	15K	17K	0	1.34M	1.71M	1.52M
Other Income/Expense	-1.18M	-1.13M	-40.69M	24.28M	11.65M	-10.6M	544K	-540K	-929K	-951K
Pretax Income+	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.43M	-23.8M	-28.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-1.53M	0	0	0	0	0	0	129K	69K	42K
Effective Tax Rate %	0.84%	1%	1%	1%	1%	0.96%	0.96%	1%	1%	1%
Net Income+	-8.22M	-11.39M	-54.49M	5.92M	-6.91M	-35.32M	-40.71M	-39.52M	-23.86M	-29.02M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.12%	-0.39%	-3.78%	1.11%	-2.17%	-4.12%	-0.15%	0.03%	0.4%	-0.22%
Net Income (Continuing)	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.56M	-23.86M	-29.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-37.62	-77.48	-370.58	26.70	21.44	-122.10	-67.80	-61.20	-16.99	-4.91
EPS Growth %	0.05%	-1.06%	-3.78%	1.07%	-0.2%	-6.69%	0.44%	0.1%	0.72%	0.71%
EPS (Basic)	-37.62	-77.48	-370.58	26.70	21.44	-4.48	-67.80	-61.20	-16.99	-4.91
Diluted Shares Outstanding	874.15K	588.15K	588.15K	886.43K	886.43K	1.28M	1.25M	1.3M	1.4M	5.91M
Basic Shares Outstanding	874.15K	588.15K	588.15K	886.43K	886.43K	1.28M	1.25M	1.3M	1.4M	5.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.91M	18.25M	18.73M	8.03M	27.41M	47.2M	34.81M	14.19M	6.07M	16.57M
Cash & Short-Term Investments	1.68M	17.75M	17.94M	7.33M	26.62M	44.48M	32.2M	12.59M	5.61M	15.64M
Cash Only	1.68M	10.22M	3.91M	7.33M	3.94M	4.32M	9.82M	8.55M	5.61M	15.64M
Short-Term Investments	0	7.53M	14.03M	0	22.68M	40.16M	22.38M	4.04M	0	0
Accounts Receivable	44K	28K	28K	24K	18K	139K	118K	298K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-24K	351K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	135.29	-	-	-	-	-
Other Current Assets	144K	217K	459K	211K	243K	673K	993K	750K	106K	602K
Total Non-Current Assets+	574K	983K	4.25M	6.45M	6.35M	28.65M	9.42M	11.78M	9.3M	8.65M
Property, Plant & Equipment	435K	847K	2.93M	6.19M	6.12M	5.89M	8.76M	11.68M	9.22M	8.37M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	219K	199K	0	0	0	0	0
Other Non-Current Assets	139K	136K	1.33M	42K	31K	22.76M	663K	99K	87K	277K
Total Assets+	2.48M	19.24M	22.98M	14.48M	33.77M	75.85M	44.23M	25.97M	15.37M	25.22M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.27%	6.76%	0.19%	-0.37%	1.33%	1.25%	-0.42%	-0.41%	-0.41%	0.64%
Total Current Liabilities+	1.67M	1.7M	3.36M	3.69M	2.58M	2.88M	8.08M	8.55M	7.29M	12.68M
Accounts Payable	0	778K	2.02M	1.13M	1.58M	974K	4.14M	1.14M	772K	2.41M
Days Payables Outstanding	-	2.24K	3.59K	1.01K	609.36	351.29	1.35K	241.99	-	-
Short-Term Debt	0	0	0	0	0	0	0	4.02M	4M	6.79M
Deferred Revenue (Current)	0	0	0	0	0	241K	269K	0	0	0
Other Current Liabilities	1.09M	377K	0	1.65M	319K	0	0	16K	1.01M	23K
Current Ratio	1.14x	10.75x	5.57x	2.18x	10.63x	16.41x	4.31x	1.66x	0.83x	1.31x
Quick Ratio	1.14x	10.75x	5.57x	2.18x	10.49x	16.41x	4.31x	1.66x	0.83x	1.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.04M	51.5M	108.27M	92.5M	251K	193K	199K	11.59M	10.18M	4.86M
Long-Term Debt	193K	0	0	0	0	0	0	7.57M	6.38M	634K
Capital Lease Obligations	-1	0	0	0	0	0	0	1.17M	857K	1.28M
Deferred Tax Liabilities	-193K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	437K	50.9M	107.67M	92.5M	251K	193K	199K	294K	398K	396K
Total Liabilities	2.71M	53.2M	111.63M	96.19M	2.83M	3.07M	8.28M	20.14M	17.47M	17.54M
Total Debt+	193K	0	0	0	0	0	0	13.73M	11.78M	9.62M
Net Debt	-1.49M	-10.22M	-3.91M	-7.33M	-3.94M	-4.32M	-9.82M	5.18M	6.17M	-6.02M
Debt / Equity	-	-	-	-	-	-	-	2.36x	-	1.25x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-6.69x	-94.99x	-862.50x	-437.24x	-1237.33x	-1545.41x	-	-29.04x	-13.36x	-18.38x
Total Equity+	-231K	-33.96M	-88.65M	-81.71M	30.93M	72.78M	35.96M	5.83M	-2.1M	7.68M
Equity Growth %	0.97%	-146.01%	-1.61%	0.08%	1.38%	1.35%	-0.51%	-0.84%	-1.36%	4.67%
Book Value per Share	-0.26	-57.74	-150.72	-92.18	34.90	56.96	28.81	4.50	-1.49	1.30
Total Shareholders' Equity	-231K	-33.96M	-88.65M	-81.71M	30.93M	72.78M	35.96M	5.83M	-2.1M	7.68M
Common Stock	126K	126K	129K	130K	130K	0	0	0	0	0
Retained Earnings	-25.18M	-36.57M	-92.31M	-86.4M	-93.3M	-132.29M	-174.89M	-214.44M	-238.31M	-267.33M
Treasury Stock	0	-2.49M	-3.54M	0	0	0	0	0	0	0
Accumulated OCI	2.02M	-561K	-766K	-1.18M	-2.12M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.57M	-9.73M	-12.31M	-16.68M	-17.36M	-21.6M	-32.39M	-34.32M	-17.24M	-21.96M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.61%	-0.48%	-0.26%	-0.35%	-0.04%	-0.24%	-0.5%	-0.06%	0.5%	-0.27%
Net Income	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.56M	-23.86M	-29.02M
Depreciation & Amortization	-108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	1.82M	1.62M
Stock-Based Compensation	0	598K	1.38M	995K	976K	4.58M	4.75M	4.31M	3.39M	2.82M
Deferred Taxes	0	0	0	0	0	0	-4.64M	0	-201K	0
Other Non-Cash Items	655K	1.17M	40.78M	-24.47M	-11.37M	11.37M	4.64M	289K	1.73M	697K
Working Capital Changes	2.41M	-237K	-187K	472K	-1.01M	-1.69M	4.35M	-1.08M	-110K	1.92M
Change in Receivables	0	0	0	0	0	-1.92M	123K	0	0	0
Change in Inventory	0	0	0	0	0	1.92M	-123K	0	0	0
Change in Payables	0	199K	385K	-887K	449K	-607K	2.22M	-3.1M	-369K	1.64M
Cash from Investing+	-102K	-8.07M	-8.38M	10.96M	-23.56M	-40.77M	36.9M	16.57M	3.8M	-330K
Capital Expenditures	-113K	-539K	-1.88M	-3.07M	-879K	-1.18M	-2.99M	-1.77M	-196K	-76K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	11K	-7.53M	-6.5M	14.03M	0	0	8M	7M	0	0
Cash from Financing+	6.19M	26.34M	14.38M	9.39M	37.65M	62.77M	1.03M	16.43M	9.98M	32.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	57K	0	68K	24K	7K	17K	0	696K	3.87M	-125K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.69M	-10.27M	-14.2M	-19.75M	-18.24M	-22.77M	-35.38M	-36.08M	-17.43M	-22.04M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.61%	-0.54%	-0.38%	-0.39%	0.08%	-0.25%	-0.55%	-0.02%	0.52%	-0.26%
FCF per Share	-7.65	-17.46	-24.14	-22.28	-20.57	-17.82	-28.35	-27.86	-12.41	-3.73
FCF Conversion (FCF/Net Income)	0.80x	0.85x	0.23x	-2.82x	2.51x	0.61x	0.80x	0.87x	0.72x	0.76x
Interest Paid	0	0	0	0	0	0	0	734K	1.04M	950K
Taxes Paid	0	0	0	0	0	0	0	8K	18K	3K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-22.32%	-68.12%	-74.88%	-189.16%	-1278.6%	-1038.73%
Return on Invested Capital (ROIC)	-	-	-	-	-	-41.28%	-68.41%	-157.03%	-227.44%	-733.23%
Debt / Equity	-	-	-	-	-	-	-	2.36x	-	1.25x
Interest Coverage	-6.69x	-94.99x	-862.50x	-437.24x	-1237.33x	-1545.41x	-	-29.04x	-13.36x	-18.38x
FCF Conversion	0.80x	0.85x	0.23x	-2.82x	2.51x	0.61x	0.80x	0.87x	0.72x	0.76x

Frequently Asked Questions

Growth & Financials

PolyPid Ltd. (PYPD) grew revenue by 0.0% over the past year. Growth has been modest.

PolyPid Ltd. (PYPD) reported a net loss of $23.9M for fiscal year 2024.

Dividend & Returns

PolyPid Ltd. (PYPD) has a return on equity (ROE) of -1038.7%. Negative ROE indicates the company is unprofitable.

PolyPid Ltd. (PYPD) had negative free cash flow of $22.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

PolyPid Ltd. (PYPD) 10-Year Financial Performance & Capital Metrics

PYPD • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$26M -25.5%
Net Income -$29M -21.6%
EPS (Diluted) -4.91 +71.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1038.73% +18.8%
ROIC -733.23% -222.4%
Debt/Equity 1.25
Interest Coverage -18.38 -37.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM75.57%

ROCE

10Y Avg-211.77%

5Y Avg-145.16%

3Y Avg-198.76%

Latest-271.8%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-108K	-127K	-205K	-411K	-947K	-1.01M	-1.12M	-1.72M	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.18%	-0.61%	-1%	-1.3%	-0.07%	-0.1%	-0.54%	1%	-
Operating Expenses+	8.57M	10.26M	13.8M	18.36M	17.61M	25.26M	42.03M	37.17M	22.87M	28.03M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.93M	2.55M	4.06M	5.81M	3.53M	9.32M	12.45M	10.9M	6.72M	5.22M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.63M	7.71M	9.74M	12.55M	14.08M	16.95M	30.42M	27.99M	16.15M	22.81M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	-1.01M	-848K	-1.72M	0	0
Operating Income+	-11.28M	-10.26M	-13.8M	-18.36M	-18.56M	-26.27M	-43.15M	-38.89M	-22.87M	-28.03M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.15%	0.09%	-0.35%	-0.33%	-0.01%	-0.42%	-0.64%	0.1%	0.41%	-0.23%
EBITDA+	-11.17M	-10.13M	-13.6M	-17.95M	-17.61M	-25.26M	-42.03M	-37.17M	-21.05M	-26.41M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.18%	0.09%	-0.34%	-0.32%	0.02%	-0.43%	-0.66%	0.12%	0.43%	-0.25%
D&A (Non-Cash Add-back)	108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	1.82M	1.62M
EBIT	-8.06M	-11.28M	-54.47M	5.96M	-6.89M	-36.87M	-42.6M	-38.09M	-22.87M	-28.03M
Net Interest Income+	-1.69M	-37K	74K	84K	45K	457K	468K	-1.07M	-1.16M	-1.08M
Interest Income	0	71K	90K	126K	60K	474K	468K	267K	548K	442K
Interest Expense	1.69M	108K	16K	42K	15K	17K	0	1.34M	1.71M	1.52M
Other Income/Expense	-1.18M	-1.13M	-40.69M	24.28M	11.65M	-10.6M	544K	-540K	-929K	-951K
Pretax Income+	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.43M	-23.8M	-28.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-1.53M	0	0	0	0	0	0	129K	69K	42K
Effective Tax Rate %	0.84%	1%	1%	1%	1%	0.96%	0.96%	1%	1%	1%
Net Income+	-8.22M	-11.39M	-54.49M	5.92M	-6.91M	-35.32M	-40.71M	-39.52M	-23.86M	-29.02M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.12%	-0.39%	-3.78%	1.11%	-2.17%	-4.12%	-0.15%	0.03%	0.4%	-0.22%
Net Income (Continuing)	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.56M	-23.86M	-29.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-37.62	-77.48	-370.58	26.70	21.44	-122.10	-67.80	-61.20	-16.99	-4.91
EPS Growth %	0.05%	-1.06%	-3.78%	1.07%	-0.2%	-6.69%	0.44%	0.1%	0.72%	0.71%
EPS (Basic)	-37.62	-77.48	-370.58	26.70	21.44	-4.48	-67.80	-61.20	-16.99	-4.91
Diluted Shares Outstanding	874.15K	588.15K	588.15K	886.43K	886.43K	1.28M	1.25M	1.3M	1.4M	5.91M
Basic Shares Outstanding	874.15K	588.15K	588.15K	886.43K	886.43K	1.28M	1.25M	1.3M	1.4M	5.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.91M	18.25M	18.73M	8.03M	27.41M	47.2M	34.81M	14.19M	6.07M	16.57M
Cash & Short-Term Investments	1.68M	17.75M	17.94M	7.33M	26.62M	44.48M	32.2M	12.59M	5.61M	15.64M
Cash Only	1.68M	10.22M	3.91M	7.33M	3.94M	4.32M	9.82M	8.55M	5.61M	15.64M
Short-Term Investments	0	7.53M	14.03M	0	22.68M	40.16M	22.38M	4.04M	0	0
Accounts Receivable	44K	28K	28K	24K	18K	139K	118K	298K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-24K	351K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	135.29	-	-	-	-	-
Other Current Assets	144K	217K	459K	211K	243K	673K	993K	750K	106K	602K
Total Non-Current Assets+	574K	983K	4.25M	6.45M	6.35M	28.65M	9.42M	11.78M	9.3M	8.65M
Property, Plant & Equipment	435K	847K	2.93M	6.19M	6.12M	5.89M	8.76M	11.68M	9.22M	8.37M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	219K	199K	0	0	0	0	0
Other Non-Current Assets	139K	136K	1.33M	42K	31K	22.76M	663K	99K	87K	277K
Total Assets+	2.48M	19.24M	22.98M	14.48M	33.77M	75.85M	44.23M	25.97M	15.37M	25.22M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.27%	6.76%	0.19%	-0.37%	1.33%	1.25%	-0.42%	-0.41%	-0.41%	0.64%
Total Current Liabilities+	1.67M	1.7M	3.36M	3.69M	2.58M	2.88M	8.08M	8.55M	7.29M	12.68M
Accounts Payable	0	778K	2.02M	1.13M	1.58M	974K	4.14M	1.14M	772K	2.41M
Days Payables Outstanding	-	2.24K	3.59K	1.01K	609.36	351.29	1.35K	241.99	-	-
Short-Term Debt	0	0	0	0	0	0	0	4.02M	4M	6.79M
Deferred Revenue (Current)	0	0	0	0	0	241K	269K	0	0	0
Other Current Liabilities	1.09M	377K	0	1.65M	319K	0	0	16K	1.01M	23K
Current Ratio	1.14x	10.75x	5.57x	2.18x	10.63x	16.41x	4.31x	1.66x	0.83x	1.31x
Quick Ratio	1.14x	10.75x	5.57x	2.18x	10.49x	16.41x	4.31x	1.66x	0.83x	1.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.04M	51.5M	108.27M	92.5M	251K	193K	199K	11.59M	10.18M	4.86M
Long-Term Debt	193K	0	0	0	0	0	0	7.57M	6.38M	634K
Capital Lease Obligations	-1	0	0	0	0	0	0	1.17M	857K	1.28M
Deferred Tax Liabilities	-193K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	437K	50.9M	107.67M	92.5M	251K	193K	199K	294K	398K	396K
Total Liabilities	2.71M	53.2M	111.63M	96.19M	2.83M	3.07M	8.28M	20.14M	17.47M	17.54M
Total Debt+	193K	0	0	0	0	0	0	13.73M	11.78M	9.62M
Net Debt	-1.49M	-10.22M	-3.91M	-7.33M	-3.94M	-4.32M	-9.82M	5.18M	6.17M	-6.02M
Debt / Equity	-	-	-	-	-	-	-	2.36x	-	1.25x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-6.69x	-94.99x	-862.50x	-437.24x	-1237.33x	-1545.41x	-	-29.04x	-13.36x	-18.38x
Total Equity+	-231K	-33.96M	-88.65M	-81.71M	30.93M	72.78M	35.96M	5.83M	-2.1M	7.68M
Equity Growth %	0.97%	-146.01%	-1.61%	0.08%	1.38%	1.35%	-0.51%	-0.84%	-1.36%	4.67%
Book Value per Share	-0.26	-57.74	-150.72	-92.18	34.90	56.96	28.81	4.50	-1.49	1.30
Total Shareholders' Equity	-231K	-33.96M	-88.65M	-81.71M	30.93M	72.78M	35.96M	5.83M	-2.1M	7.68M
Common Stock	126K	126K	129K	130K	130K	0	0	0	0	0
Retained Earnings	-25.18M	-36.57M	-92.31M	-86.4M	-93.3M	-132.29M	-174.89M	-214.44M	-238.31M	-267.33M
Treasury Stock	0	-2.49M	-3.54M	0	0	0	0	0	0	0
Accumulated OCI	2.02M	-561K	-766K	-1.18M	-2.12M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.57M	-9.73M	-12.31M	-16.68M	-17.36M	-21.6M	-32.39M	-34.32M	-17.24M	-21.96M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.61%	-0.48%	-0.26%	-0.35%	-0.04%	-0.24%	-0.5%	-0.06%	0.5%	-0.27%
Net Income	-9.75M	-11.39M	-54.49M	5.92M	-6.91M	-36.87M	-42.6M	-39.56M	-23.86M	-29.02M
Depreciation & Amortization	-108K	127K	205K	411K	947K	1.01M	1.12M	1.72M	1.82M	1.62M
Stock-Based Compensation	0	598K	1.38M	995K	976K	4.58M	4.75M	4.31M	3.39M	2.82M
Deferred Taxes	0	0	0	0	0	0	-4.64M	0	-201K	0
Other Non-Cash Items	655K	1.17M	40.78M	-24.47M	-11.37M	11.37M	4.64M	289K	1.73M	697K
Working Capital Changes	2.41M	-237K	-187K	472K	-1.01M	-1.69M	4.35M	-1.08M	-110K	1.92M
Change in Receivables	0	0	0	0	0	-1.92M	123K	0	0	0
Change in Inventory	0	0	0	0	0	1.92M	-123K	0	0	0
Change in Payables	0	199K	385K	-887K	449K	-607K	2.22M	-3.1M	-369K	1.64M
Cash from Investing+	-102K	-8.07M	-8.38M	10.96M	-23.56M	-40.77M	36.9M	16.57M	3.8M	-330K
Capital Expenditures	-113K	-539K	-1.88M	-3.07M	-879K	-1.18M	-2.99M	-1.77M	-196K	-76K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	11K	-7.53M	-6.5M	14.03M	0	0	8M	7M	0	0
Cash from Financing+	6.19M	26.34M	14.38M	9.39M	37.65M	62.77M	1.03M	16.43M	9.98M	32.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	57K	0	68K	24K	7K	17K	0	696K	3.87M	-125K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.69M	-10.27M	-14.2M	-19.75M	-18.24M	-22.77M	-35.38M	-36.08M	-17.43M	-22.04M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.61%	-0.54%	-0.38%	-0.39%	0.08%	-0.25%	-0.55%	-0.02%	0.52%	-0.26%
FCF per Share	-7.65	-17.46	-24.14	-22.28	-20.57	-17.82	-28.35	-27.86	-12.41	-3.73
FCF Conversion (FCF/Net Income)	0.80x	0.85x	0.23x	-2.82x	2.51x	0.61x	0.80x	0.87x	0.72x	0.76x
Interest Paid	0	0	0	0	0	0	0	734K	1.04M	950K
Taxes Paid	0	0	0	0	0	0	0	8K	18K	3K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-22.32%	-68.12%	-74.88%	-189.16%	-1278.6%	-1038.73%
Return on Invested Capital (ROIC)	-	-	-	-	-	-41.28%	-68.41%	-157.03%	-227.44%	-733.23%
Debt / Equity	-	-	-	-	-	-	-	2.36x	-	1.25x
Interest Coverage	-6.69x	-94.99x	-862.50x	-437.24x	-1237.33x	-1545.41x	-	-29.04x	-13.36x	-18.38x
FCF Conversion	0.80x	0.85x	0.23x	-2.82x	2.51x	0.61x	0.80x	0.87x	0.72x	0.76x

Frequently Asked Questions

Growth & Financials

PolyPid Ltd. (PYPD) grew revenue by 0.0% over the past year. Growth has been modest.

PolyPid Ltd. (PYPD) reported a net loss of $23.9M for fiscal year 2024.

Dividend & Returns

PolyPid Ltd. (PYPD) has a return on equity (ROE) of -1038.7%. Negative ROE indicates the company is unprofitable.

PolyPid Ltd. (PYPD) had negative free cash flow of $22.0M in fiscal year 2024, likely due to heavy capital investments.